Boston Scientific Corporation (NYSE:BSX) Shares Acquired by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC increased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 11.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 253,364 shares of the medical equipment provider's stock after buying an additional 25,449 shares during the period. Commonwealth Equity Services LLC's holdings in Boston Scientific were worth $25,559,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Capital World Investors grew its position in shares of Boston Scientific by 28.7% in the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock valued at $2,492,041,000 after purchasing an additional 6,216,199 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Boston Scientific by 11,720.3% in the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock valued at $260,057,000 after purchasing an additional 2,556,078 shares during the last quarter. Northern Trust Corp grew its position in shares of Boston Scientific by 18.0% in the fourth quarter. Northern Trust Corp now owns 14,595,627 shares of the medical equipment provider's stock valued at $1,303,681,000 after purchasing an additional 2,221,790 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Boston Scientific by 18.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after purchasing an additional 1,709,461 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of Boston Scientific by 161.9% in the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock valued at $250,757,000 after purchasing an additional 1,536,663 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Leerink Partners began coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 target price on the stock. UBS Group raised their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Truist Financial raised their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Finally, BTIG Research restated a "buy" rating and set a $124.00 target price on shares of Boston Scientific in a research report on Wednesday, April 23rd. Two research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Boston Scientific presently has an average rating of "Buy" and an average price target of $117.50.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the transaction, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This represents a 10.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 345,029 shares of company stock worth $35,976,603. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Down 0.1%

Shares of BSX stock traded down $0.06 during mid-day trading on Thursday, reaching $102.89. The company's stock had a trading volume of 5,405,736 shares, compared to its average volume of 7,704,204. The company's 50 day simple moving average is $103.58 and its 200-day simple moving average is $102.04. Boston Scientific Corporation has a 12-month low of $74.01 and a 12-month high of $108.94. The company has a quick ratio of 0.88, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $152.46 billion, a PE ratio of 61.25, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the firm posted $0.62 EPS. The business's revenue for the quarter was up 22.8% compared to the same quarter last year. On average, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.